Physician profile
Reed B Mitchell
NPI 1225091267
$5,593.36
in general payments reported to CMS, 2019-2025
53 companies · $1,584 in 2025
The $1,584 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $293 · 2021: $29.53 · 2022: $504 · 2023: $1,258 · 2024: $1,924 · 2025: $1,584.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,766.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,766.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $856.23 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $610.71 | 2021-2025 | Lynparza, Calquence, Enhertu |
| Pfizer INC. | $361.85 | 2022-2025 | |
| Tersera Therapeutics LLC | $324.02 | 2023-2025 | Zoladex, Xermelo |
| Ipsen Biopharmaceuticals, INC | $301.88 | 2022-2025 | Onivyde, Somatuline Depot |
| Genentech USA, INC. | $294.47 | 2019-2025 | Tecentriq, Alecensa, Rozlytrek |
| Merck Sharp & Dohme LLC | $260.72 | 2023-2025 | Keytruda, Welireg, Reblozyl |
| Eisai INC. | $211.50 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $154.46 | 2022-2025 | |
| Kite Pharma, INC. | $137.11 | 2019-2023 | Yescarta |
| Abbvie INC. | $132.49 | 2022-2025 | |
| Incyte Corporation | $116.68 | 2023-2025 | Pemazyre, Monjuvi, Jakafi |
| Emd Serono, INC. | $102.92 | 2023-2025 | Tepmetko, Bavencio |
| Daiichi Sankyo INC. | $91.61 | 2022-2025 | Enhertu, Injectafer |
| E.R. Squibb & Sons, L.L.C. | $88.01 | 2022-2023 | Opdivo, Opdualag |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $87.36 | 2022-2025 | |
| Janssen Biotech, INC. | $80.00 | 2019-2025 | Talvey, Darzalex, Tecvayli |
| Seagen INC. | $79.67 | 2019-2023 | Adcetris |
| Karyopharm Therapeutics INC. | $78.65 | 2023-2024 | Xpovio |
| Lilly USA, LLC | $71.13 | 2023-2024 | Jaypirca, Verzenio, Retevmo |
| Regeneron Healthcare Solutions, INC. | $65.36 | 2023-2025 | Libtayo |
| Astellas Pharma US INC | $64.01 | 2022-2025 | Vyloy, Xospata |
| Jazz Pharmaceuticals INC. | $62.65 | 2022-2025 | |
| Puma Biotechnology, INC. | $60.41 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.93 | 2019 | |
| Amgen INC. | $56.78 | 2023 | Lumakras, Xgeva, Vectibix |
| Blueprint Medicines Corporation | $56.27 | 2023-2025 | Ayvakit |
| Takeda Pharmaceuticals U.S.A., INC. | $55.85 | 2024-2025 | Alunbrig, Fruzaqla |
| Array Biopharma INC | $51.30 | 2024-2025 | Braftovi, Mektovi, Tukysa |
| Gilead Sciences, INC. | $48.97 | 2021-2024 | |
| Deciphera Pharmaceuticals INC. | $48.68 | 2023-2025 | Qinlock, Romvimza |
| Celgene Corporation | $45.96 | 2019-2023 | Reblozyl |
| Pharmacyclics LLC, An Abbvie Company | $44.27 | 2022-2023 | Imbruvica, Epkinly |
| Progenics Pharmaceuticals, INC. | $40.96 | 2024-2025 | |
| Alnylam Pharmaceuticals INC. | $33.25 | 2024 | Givlaari |
| Cti Biopharma Corp. | $32.78 | 2022 | |
| Aveo Pharmaceuticals, INC. | $32.29 | 2023-2024 | Fotivda |
| Glaxosmithkline, LLC. | $30.97 | 2025 | Ojjaara |
| Apellis Pharmaceuticals, INC. | $30.45 | 2023-2024 | Empaveli |
| Pharmaessentia USA Corporation | $30.01 | 2025 | Besremi |
| Taiho Oncology, INC. | $28.84 | 2024 | |
| Geron Corporation | $26.31 | 2025 | Rytelo |
| Rigel Pharmaceuticals, INC. | $25.73 | 2022-2023 | Rezlidhia, Tavalisse |
| Pharmacosmos Therapeutics INC. | $24.87 | 2025 | Monoferric |
| Coherus Oncology, INC. | $18.07 | 2023 | |
| Agios Pharmaceuticals, INC. | $17.76 | 2025 | Pyrukynd |
| Caris Mpi, INC. | $17.25 | 2025 | Mi Cancer Seek |
| Morphosys, US INC. | $15.69 | 2023 | Monjuvi |
| Adc Therapeutics America, INC. | $14.76 | 2024 | |
| Sumitomo Pharma America, INC. | $14.46 | 2023 | Orgovyx |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reed Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.